There are currently 22 clinical trials in Cape Coral, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Florida Cancer Specialists. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Florida Cancer Specialists,1030 Commerce Creek Blvd, Cape Coral, Florida
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
05/08/2024
Locations: Renaissance Research and Medical Group, Cape Coral, Florida
Conditions: Atopic Dermatitis
Register for Updates
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
NCT06073119
Recruiting
This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It is designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details include a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (2 weeks ± 3 days). The total number... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/08/2024
Locations: Renaissance Research and Medical Group, Inc Site Number : 8400018, Cape Coral, Florida
Conditions: Psoriasis
Register for Updates
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Florida Cancer Specialists,1030 Commerce Creek Blvd, Cape Coral, Florida
Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Register for Updates
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445
Recruiting
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/02/2024
Locations: Renaissance Research, Cape Coral, Florida
Conditions: NonSegmental Vitiligo
Register for Updates
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT04464564
Recruiting
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
04/30/2024
Locations: Clinical Research Site #840-096, Cape Coral, Florida
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Register for Updates
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267
Recruiting
The primary objective of the study is to demonstrate the efficacy of high dose and low dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs). Secondary Objectives: To evaluate the efficacy of Fp/ABS compared to ABS and the effect on systemic corticosteroid (SCS) exposure To evaluate the safety and tolerability of Fp/A BS The duration for each part... Read More
Gender:
All
Ages:
4 years and above
Trial Updated:
04/29/2024
Locations: Teva Investigational Site 15624, Cape Coral, Florida
Conditions: Asthma
Register for Updates
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535
Recruiting
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). **************************... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
04/25/2024
Locations: Florida Cancer Specialists South / Sarah Cannon Research Institute, Cape Coral, Florida
Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Register for Updates
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
NCT05654623
Recruiting
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Florida Cancer Specialists NFM, Cape Coral, Florida
Conditions: Advanced Breast Cancer
Register for Updates
Phase 2 Study of DKN-01 in Colorectal Cancer
NCT05480306
Recruiting
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced CRC patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2024
Locations: Florida Cancer Specialists & Research Institute (FCS), Cape Coral, Florida
Conditions: Colorectal Cancer, Colorectal Adenocarcinoma, Colo-rectal Cancer, Colorectal Cancer Metastatic
Register for Updates
Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.
NCT05569005
Recruiting
The purpose of this study is to demonstrate the slowing of the disease progression including the improvement of Chronic Obstructive Pulmonary Disease (COPD) symptoms in smoking subjects with mild to moderate COPD and a history of chronic bronchitis symptoms (sputum and cough) who switch to the Tobacco Heating System (THS) as compared to those who continue to smoke cigarettes.
Gender:
All
Ages:
Between 35 years and 65 years
Trial Updated:
04/19/2024
Locations: US97; Riverside Research Group, Cape Coral, Florida
Conditions: COPD, Smoking, Tobacco Use
Register for Updates
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
NCT05979779
Recruiting
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) during this time. The end-of-study visit will take place approximately 4 weeks after the last dose of the study drug (Week 30).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: ABMED Clinical Research Corp., Cape Coral, Florida
Conditions: Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
Register for Updates